Journal
CANCER CELL
Volume 22, Issue 3, Pages 345-358Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2012.08.007
Keywords
-
Categories
Funding
- National Institutes of Health [P50100707, PO1-CA078378, R43DK071391, R43CA115205]
- [VR-2011-2686]
- Medical Research Council [G0501068] Funding Source: researchfish
- MRC [G0501068] Funding Source: UKRI
Ask authors/readers for more resources
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility. Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies. Biochemical and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity. In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival. Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity. Our preclinical study therefore supports clinical evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available